Compare · CBLL vs LHDX
CBLL vs LHDX
Side-by-side comparison of CeriBell Inc. (CBLL) and Lucira Health Inc. (LHDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and LHDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CBLL carries a market cap of $1.08B.
- CBLL has hit the wire 9 times in the past 4 weeks while LHDX has been quiet.
- CBLL has more recent analyst coverage (8 ratings vs 0 for LHDX).
- Company
- CeriBell Inc.
- Lucira Health Inc.
- Price
- -
- -
- Market cap
- $1.08B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 8
- 0
Lucira Health Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Latest CBLL
- SEC Form 144 filed by CeriBell Inc.
- Director Taylor Joseph Michael sold $277,644 worth of shares (10,200 units at $27.22), decreasing direct ownership by 21% to 38,278 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $131,754 worth of shares (4,887 units at $26.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by CeriBell Inc.
- CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ceribell Reports Third Quarter 2026 Financial Results
- Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
Latest LHDX
- SEC Form 15-12G filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership
- SEC Form NT 10-Q filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Lucira Health Inc.